OMB APPROVAL OMB Number: 3235-0145 Expires: October 31, 2002 Estimated average burden hours per response. . . 14.9

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. ____)*

NEUROCRINE BIOSCIENCES, INC.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

64125C109

(CUSIP Number)

MARCH 9, 2001

(Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[] Rule 13d-1(b)
[X] Rule 13d-1(c)
[] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed " for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8

CUSIP No.	64125C109			
1.	Names of Reporting Persons		TECH TARGET S.A.	
	I.R.S. Identification Nos. of	above	e persons (entities only):	N/A
2.	Check the Appropriate Box if (a) [X] (b) []	a Meml	per of a Group (See Instructi	.ons)
3.	SEC Use Only			
4.	Citizenship or Place of Organ	izatio	on REPUBLIC	COF PANAMA
Number of Shares Beneficially Owned by Each Reporting Person with:		5.	Sole Voting Power	0
		6.	Shared Voting Power	1,343,500
		7.	Sole Dispositive Power	0
		8.	Shared Dispositive Power	1,343,500
9.	Aggregate Amount Beneficially by Each Reporting Person	owned		1,343,500
10.	Check if the Aggregate Amount	in Ro	ow (9) Excludes Certain Share	es []
11.	Percent of Class Represented	by amo	ount in Row (9)	5.4%
12.	Type of Reporting Person (See	e Insti	ructions)	со

Page 2 of 8

CUSIP No.	64125C109				
1.	Names of Reporting Persons		BB BIOTE	CH AG	
	I.R.S. Identification Nos. of	⁼ abov	e persons (entities only):	N/A	
2.	Check the Appropriate Box if (a) [X] (b) []	a Mem	ber of a Group (See Instruc	tions)	
3.	SEC Use Only				
4.	Citizenship or Place of Orgar	nizati	on SW	ITZERLAND	
Number of Shares Beneficially Owned by Each Reporting Person with:		5.	Sole Voting Power	0	
Fei Sui	i with.	6. Shared Voting Power		1,343,500	
		7.	Sole Dispositive Power	0	
		8.	Shared Dispositive Power	1,343,500	
9.	Aggregate Amount Beneficially by Each Reporting Person	/ Owne		1,343,500	
10.	Check if the Aggregate Amount	: in R	ow (9) Excludes Certain Sha	res []	
11.	Percent of Class Represented	by am	ount in Row (9)	5.4%	
12.	Type of Reporting Person (See	e Inst		HC,CO	

Page 3 of 8

ITEM 1

ITEM 2

4

1(a)		NEUROCRINE BIOSCIENCES, INC.
1(b)	Address of Issuer's Prin	
2(a)	Name of Person Filing:	BB BIOTECH AG ("BB BIOTECH"), ON BEHALF
	OF BIOTECH TARGET S.A. ("BIOTARGET"), ITS WHOLLY-OWNED
	SUBSIDIARY AND RECORD OW	
2(b)	Address of Principal Bus	iness Office or, if none, Residence:
	BB BIOTECH AG: VODERGA	SSE 3, CH-8300 SCHAFFHAUSEN, SWITZERLAND
		CALLE 53, URBANIZACION OBARRIO, TORRE SWISS BANK, PISO 16, PANAMA CITY, ZONA 1, REPUBLIC OF PANAMA
2(c)	Citizenship:	SWITZERLAND
2(d)	Title of Class of Securi	ties COMMON STOCK
2(e)	CUSIP Number	64125C109

ITEM 3

IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- a. [] Broker or Dealer registered under Section 15 of the Act.
- b. [] Bank as defined in Section 3(a)(6) of the Act.
- c. [] Insurance company as defined in Section 3(a)(19) of the Act.
- d. [] Investment company registered under section 8 of the Investment Company Act of 1940.
- e. [] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- f. [] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- g. [] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- h. [] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- [] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- j. [] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

5

τт	ΈМ	Δ	OWNERSHIP
- 1		÷.	OWNERSHIF

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

	(a)	Amount benef	icially owned:		1,343,500		
	(b)	Percent of c	class:		5.4%		
	(c)	Number of sh	nares as to which	the person has	:		
		(i) Sole p	oower to vote or t	to direct the v	ote		0
		(ii) Shared	d power to vote of	r to direct the	vote		1,343,500
		(iii) Sole p	oower to dispose (or to direct th	e disposition of		0
		(iv) Shared	d power to dispose	e or to direct	the disposition of		1,343,500
ITEM 5.	OWNERS	HIP OF FIVE F	PERCENT OR LESS OF	= A CLASS			
	the repo	rting person		the beneficial	t that as of the da owner of more than g: []		
ITEM 6.	OWNERS	HIP OF MORE T	HAN FIVE PERCENT	ON BEHALF OF A	NOTHER PERSON.		
			N/A				
	CURITY B THIS S	EING REPORTED	ON BY THE PAREN	T HOLDING COMPA 3B BIOTECH AND	WHICH ACQUIRED TH NY OR CONTROL PERS(BIOTARGET. BIOTARGE	ON.	
ITEM 8.	IDENTI	FICATION AND	CLASSIFICATION O	F MEMBERS OF TH	E GROUP		
ITEM 9.	NOTICE	OF DISSOLUTI	ION OF GROUP				
			N/A				

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

			BB BIOTECH AG
Date:	March 21, 2001	By:	/s/ Anders Hove
		Name:	Anders Hove
		Title:	Signatory Authority
Date:	March 21, 2001	By:	/s/ Dubravka Racnjak
		Name:	Dubravka Racnjak
		Title:	Signatory Authority
			BIOTECH TARGET S.A.
Date:	March 21, 2001	By:	/s/ Anders Hove
		Name:	Anders Hove
		Title:	Signatory Authority
Date:	March 21, 2001	By:	/s/ Dubravka Racnjak
		Name:	Dubravka Racnjak
		Title:	Signatory Authority

Page 6 of 8

EXHIBIT INDEX

Exhibit A:	Agreemen	t by a	nd between	BB Biotech	and BioTarget with
	respect	to the	filing of	this discl	osure statement.

Page 7 of 8

EXHIBIT A

JOINT FILING STATEMENT

Pursuant to Rule 13d-1(f)(1), we, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

BB BIOTECH AG

Date:	March 21, 2001	By:	/s/ Anders Hove
		Name:	Anders Hove
		Title:	Signatory Authority
Date:	March 21, 2001	By:	/s/ Dubravka Racnjak
		Name:	Dubravka Racnjak
		Title:	Signatory Authority
			BIOTECH TARGET S.A.
Date:	March 21, 2001	By:	/s/ Anders Hove
		Name:	Anders Hove
		Title:	Signatory Authority
Date:	March 21, 2001	By:	/s/ Dubravka Racnjak
		Name:	Dubravka Racnjak
		Title:	Signatory Authority

Page 8 of 8